February 17, 2022
Intellia and ONK Therapeutics announce collaboration to advance allogeneic CRISPR-edited NK cell therapies for the treatment of patients with cancer
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a genome editing company focused on developing curative therapies leveraging CRISPR-based technologies, and ONK Therapeutics Ltd.,…